Halozyme Therapeutics Inc. (HALO)
BMV
Closed
Aug 21, 2026
Day's Range
1,740.0052 wk Range
1,121.86Overview - HALO - Halozyme Therapeutics Inc.
Key Statistics
Valuation
Enterprise Value
3.37T
P/E (Trailing)
‪30.11‬
PEG Ratio
‪0.68‬
Price / Sales (TTM)
‪118.70‬
Price / Book
‪81.11‬
EV / EBITDA
‪189.81‬
Profitability
Gross Margin
‪83.54%‬
Profit Margin
‪24.85%‬
Operating Margin
‪59.80%‬
Return on Assets
‪25.49%‬
Return on Equity
‪173.67%‬
Ownership
Shares Outstanding
118.61M
Float
112.16M
Held by Insiders
‪1.10%‬
Held by Institutions
‪112.34%‬
Price stats
Beta
‪0.84‬
50-Day Avg
‪1,411.07‬
200-Day Avg
‪1,270.50‬
Dividends
Payout Ratio
‪0.00%‬
Shariah Compliance
Report Date: Feb 19, 2025
Screened by Zoya using the AAOIFI methodology.
Peers - HALO - Halozyme Therapeutics Inc.
Peer Comparison
Compared with companies in Biotechnology listed on BMV.
- HALOBMVHalozyme Therapeutics Inc.197.48BMarket Cap+35.52%52-week change29.94P/E (Trailing)‪24.85%‬Profit Margin
- ARGXNBMVargenx SE American Depositary Receipt931.67BMarket Cap+4.58%52-week change33.44P/E (Trailing)‪32.26%‬Profit Margin
- ALNYBMVAlnylam Pharmaceuticals Inc742.50BMarket Cap-54.26%52-week change57.14P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNBMVBioNTech SE492.36BMarket Cap+4.53%52-week change1.65P/E (Trailing)‪-63.63%‬Profit Margin
- BMRNBMVBioMarin Pharmaceutical Inc.218.20BMarket Cap+4.43%52-week change178.64P/E (Trailing)‪2.14%‬Profit Margin
- ACADBMVAcadia Pharmaceuticals Inc.77.69BMarket Cap-12.18%52-week change13.49P/E (Trailing)‪33.41%‬Profit Margin
- AGIOBMVAgios Pharmaceuticals Inc.72.95BMarket Cap+0.00%52-week change5.17P/E (Trailing)‪88.25%‬Profit Margin
Profile Summary - HALO - Halozyme Therapeutics Inc.
About
Halozyme Therapeutics Inc. is a biopharmaceutical company that researches, develops, and commercializes proprietary enzymes and drug delivery technologies. Its core platform centers on the patented recombinant human hyaluronidase enzyme (rHuPH20), enabling subcutaneous administration of injectable biologics like…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
